头颈部肿瘤立体定向再照射治疗:Oscar Lambret中心长期经验的回顾性研究
该回顾性研究纳入2007至2020年在Oscar Lambret中心接受36 Gy分6次立体定向再照射(CyberKnife®)的110例复发/第二原发头颈癌患者,中位随访106.3个月,2年总生存率43.8%,中位生存20.8个月,2年局部复发累积发生率52.2%,≥2级晚期毒性24个月累积发生率42%。作者认为该治疗可行,但局部复发率仍不可忽视,需进一步研究。
要点
- 110例复发/第二原发头颈癌患者接受36 Gy分6次CyberKnife®立体定向再照射,中位随访106.3个月。
- 2年总生存率43.8%(95%CI 34.3-52.9),中位生存20.8个月(95%CI 16.5-26.3)。
- 73例接受同期西妥昔单抗未见显著获益(HR=1.34;95%CI 0.80-2.26;p=0.26)。
核心结论
- 作者认为,对于复发或第二原发头颈癌,立体定向再照射治疗是可行的,但局部复发率仍不可忽视,需进一步研究。
- 作者指出,目前正在研究放射增敏剂的使用,因此平衡治疗调整与毒性至关重要。
研究设计与样本
- 本研究为回顾性系列研究,纳入2007年至2020年在Oscar Lambret中心接受36 Gy分6次立体定向再照射(CyberKnife®)的110例复发/第二原发头颈癌患者。
- 评估患者特征与毒性,采用Kaplan-Meier法估计总生存(OS)和无进展生存(PFS)。
主要发现
- 中位随访时间为106.3个月。
- 2年OS率为43.8%(95%CI 34.3-52.9),中位生存为20.8个月(95%CI 16.5-26.3)。
- 2年局部复发、区域复发和远处转移的累积发生率分别为52.2%(95%CI 42.4-61.1%)、12.8%(95%CI 7.4-19.8%)和11%(95%CI 6.0-17.6%)。
- 73例患者接受同期西妥昔单抗,未见显著获益(HR=1.34;95%CI 0.80-2.26;p=0.26)。
- ≥2级晚期毒性24个月累积发生率为42%(95%CI 33-51),报告2例4级出血,无治疗相关死亡。
关键数值与推荐
- 立体定向再照射方案为36 Gy分6次(CyberKnife®)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性研究。
- 作者指出局部复发率仍不可忽视,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Stereotactic radiotherapy potentially treats unresectable recurrences of previously irradiated head and neck (H&N) cancer. This study aimed to assess its efficacy and safety and evaluate prognostic factors. MATERIALS AND METHODS: We conducted a large retrospective series that included 110 patients who had undergone 36-Gy, six-fraction stereotactic reirradiation (CyberKnife®) for recurrent/secondary H&N cancer between 2007 and 2020 at the Oscar Lambret Center. Patient characteristics and toxicities were assessed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. RESULTS: Median follow-up time was 106.3 months. The 2-year OS rate was 43.8 % (95 % confidence interval, 95 % CI, 34.3-52.9) and the median survival was 20.8 months (95 % CI, 16.5-26.3). The cumulative 2-year local-recurrence, regional-recurrence, and distant-metastasis rates were 52.2 % (95 % CI, 42.4-61.1 %), 12.8 % (95 % CI, 7.4-19.8 %), and 11 % (95 % CI, 6.0-17.6 %), respectively. 73 patients received concomitant cetuximab, and it was not significantly beneficial (HR = 1.34; 95 % CI, 0.80-2.26; p = 0.26). The cumulative incidences of grade ≥ 2 late toxicity was 42 % (CI95%: 33-51) at 24 months. Two grade 4 bleedings and no treatment-related deaths were reported. CONCLUSION: In a large retrospective series of SBRT reirradiation for recurrent or second primary H&N cancers, we observed a median OS of 20.8 months, with a cumulative incidence of grade ≥ 2 late toxicity of 42 % at 24 months. Such a treatment is feasible. However, local recurrence rates remain non-negligible, warranting further research. Radiosensitizer use is currently under study. Therefore, establishing a balance between therapeutic modifications and toxicity is essential.
引用
- Delerue C, Pasquier D, Bogart E, et al. Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center. Radiother Oncol. 2023. PMID: 38007041. doi:10.1016/j.radonc.2023.110029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。